 Connection
Samer Al Hadidi to Hematopoietic Stem Cell Transplantation
This is a "connection" page, showing publications Samer Al Hadidi has written about Hematopoietic Stem Cell Transplantation.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.141 |
|
|
|
-
Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Tricot G, Shaughnessy J, Zhan F, Sawyer J, Siegel ER, Zangari M, Barlogie B, van Rhee F. Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2024 Nov; 99(11):2222-2224.
Score: 0.691
-
Ali MO, Al Hadidi S. High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma. Transplant Cell Ther. 2022 09; 28(9):572-580.
Score: 0.596
-
Al-Hadidi SA, Lee HJ. Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma. JCO Oncol Pract. 2021 02; 17(2):64-71.
Score: 0.539
-
Caro J, Al Hadidi S, Usmani S, Yee AJ, Raje N, Davies FE. How to Treat High-Risk Myeloma at Diagnosis and Relapse. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:291-309.
Score: 0.136
-
Al Hadidi SA, Lee HJ. Pembrolizumab for the treatment of Hodgkin Lymphoma. Expert Opin Biol Ther. 2020 11; 20(11):1275-1282.
Score: 0.133
-
Biltibo EMD, Surapaneni M, Al Hadidi S, Suvannasankha A, Jayani-Kosarzycki RV. Current and Future Directions of Immunotherapies in Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2025 Jun; 45(3):e473316.
Score: 0.046
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|